<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32344926</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>25</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Inhibition of RNA Helicase Activity Prevents Coxsackievirus B3-Induced Myocarditis in Human iPS Cardiomyocytes.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3041</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21093041</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Coxsackievirus B3 (CVB3) is known to be an important cause of myocarditis and dilated cardiomyopathy. Enterovirus-2C (E2C) is a viral RNA helicase. It inhibits host protein synthesis. Based on these facts, we hypothesize that the inhibition of 2C may suppress virus replication and prevent enterovirus-mediated cardiomyopathy.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">We generated a chemically modified enterovirus-2C inhibitor (E2CI). From the in vitro assay, E2CI was showed strong antiviral effects. For in vivo testing, mice were treated with E2CI intraperitoneally injected daily for three consecutive days at a dose of 8mg/kg per day, after CVB3 post-infection (p.i) (CVB3 + E2CI, <i>n</i> = 33). For the infected controls (CVB3 only, <i>n</i> = 35), mice were injected with PBS (phosphate buffered saline) in a DBA/2 strain to establish chronic myocarditis. The four-week survival rate of E2CI-treated mice was significantly higher than that of controls (92% vs. 71%; <i>p</i> &lt; 0.05). Virus titers and myocardial damage were significantly reduced in the E2CI treated group. In addition, echocardiography indicated that E2CI administration dramatically maintained mouse heart function compared to control at day 28 p.i chronic stage (LVIDD, 3.1 &#xb1; 0.08 vs. 3.9 &#xb1; 0.09, <i>p</i> &lt; 0.01; LVDS, 2.0 &#xb1; 0.07 vs. 2.5 &#xb1; 0.07, <i>p</i> &lt; 0.001; FS, 34.8 &#xb1; 1.6% vs. 28.5 &#xb1; 1.5%; EF, 67. 9 &#xb1; 2.9% vs. 54.7 &#xb1; 4.7%, <i>p</i> &lt; 0.05; CVB3 + E2CI, <i>n</i> = 6 vs. CVB3, <i>n</i> = 4). Moreover, E2CI is effectively worked in human iPS (induced pluripotent stem cell) derived cardiomyocytes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Enterovirus-2C inhibitor (E2CI) was significantly reduced viral replication, chronic myocardium damage, and CVB3-induced mortality in DBA/2 mice. These results suggested that E2CI is a novel therapeutic agent for the treatment of enterovirus-mediated diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yun</LastName><ForeName>Soo-Hyeon</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Samsung Medical Center, Sungkyunkwan University School of Medicine 50 Irwon dong, Gangnam-gu, Seoul 06351, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Ha-Hyeon</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Department of Biomedical Science, Jungwon University, 85 Munmu-ro, Goesan-gun 28024, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ju</LastName><ForeName>Eun-Seon</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Samsung Medical Center, Sungkyunkwan University School of Medicine 50 Irwon dong, Gangnam-gu, Seoul 06351, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>You-Jung</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Samsung Medical Center, Sungkyunkwan University School of Medicine 50 Irwon dong, Gangnam-gu, Seoul 06351, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Byung-Kwan</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Department of Biomedical Science, Jungwon University, 85 Munmu-ro, Goesan-gun 28024, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Eun-Seok</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Samsung Medical Center, Sungkyunkwan University School of Medicine 50 Irwon dong, Gangnam-gu, Seoul 06351, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NRF-2018R1A2B2003628</GrantID><Agency>National Research Foundation of Korea</Agency><Country/></Grant><Grant><GrantID>NRF-2019R1F1A1057678</GrantID><Agency>National Research Foundation of Korea</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010069">Oxadiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010080">Oxazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9H4570Q89D</RegistryNumber><NameOfSubstance UI="C115201">pleconaril</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.13.12.5</RegistryNumber><NameOfSubstance UI="D049410">Luciferases, Renilla</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D020365">RNA Helicases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002311" MajorTopicYN="N">Cardiomyopathy, Dilated</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="N">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049410" MajorTopicYN="N">Luciferases, Renilla</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008811" MajorTopicYN="N">Mice, Inbred DBA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="N">Myocarditis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010069" MajorTopicYN="N">Oxadiazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010080" MajorTopicYN="N">Oxazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020365" MajorTopicYN="N">RNA Helicases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018487" MajorTopicYN="N">Ventricular Dysfunction, Left</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiomyopathy</Keyword><Keyword MajorTopicYN="N">coxsackievirus B3</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">helicase</Keyword><Keyword MajorTopicYN="N">iPSC</Keyword><Keyword MajorTopicYN="N">myocarditis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32344926</ArticleId><ArticleId IdType="pmc">PMC7246926</ArticleId><ArticleId IdType="doi">10.3390/ijms21093041</ArticleId><ArticleId IdType="pii">ijms21093041</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yun S.H., Lee W.G., Kim Y.C., Ju E.S., Lim B.K., Choi J.O., Kim D.K., Jeon E.S. Antiviral activity of coxsackievirus B3 3C protease inhibitor in experimental murine myocarditis. J. Infect. Dis. 2012;205:491&#x2013;497. doi: 10.1093/infdis/jir745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jir745</ArticleId><ArticleId IdType="pubmed">22207647</ArticleId></ArticleIdList></Reference><Reference><Citation>Baboonian C., Davies M.J., Booth J.C., McKenna W.J. Coxsackie B viruses and human heart disease. Curr. Top. Microbiol. Immunol. 1997;223:31&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">9294924</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskowitz A., Beisel K.W., Wolfgram L.J., Rose N.R. Coxsackievirus B3 murine myocarditis: Wide pathologic spectrum in genetically defined inbred strains. Hum. Pathol. 1985;16:671&#x2013;673. doi: 10.1016/S0046-8177(85)80149-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0046-8177(85)80149-0</ArticleId><ArticleId IdType="pubmed">2989148</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman A.M., McNamara D. Myocarditis. N. Engl. J. Med. 2000;343:1388&#x2013;1398. doi: 10.1056/NEJM200011093431908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200011093431908</ArticleId><ArticleId IdType="pubmed">11070105</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlton K.U., Badorff C. The immune system in viral myocarditis: Maintaining the balance. Circ. Res. 1999;85:559&#x2013;561. doi: 10.1161/01.RES.85.6.559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.85.6.559</ArticleId><ArticleId IdType="pubmed">10488059</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlton K.U., Jeon E.S., Berkley N., Wessely R., Huber S. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J. Virol. 1996;70:7811&#x2013;7818. doi: 10.1128/JVI.70.11.7811-7818.1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.70.11.7811-7818.1996</ArticleId><ArticleId IdType="pmc">PMC190851</ArticleId><ArticleId IdType="pubmed">8892902</ArticleId></ArticleIdList></Reference><Reference><Citation>Badorff C., Lee G.H., Lamphear B.J., Martone M.E., Campbell K.P., Rhoads R.E., Knowlton K.U. Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat. Med. 1999;5:320&#x2013;326. doi: 10.1038/6543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/6543</ArticleId><ArticleId IdType="pubmed">10086389</ArticleId></ArticleIdList></Reference><Reference><Citation>Esfandiarei M., Luo H., Yanagawa B., Suarez A., Dabiri D., Zhang J., McManus B.M. Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent. J. Virol. 2004;78:4289&#x2013;4298. doi: 10.1128/JVI.78.8.4289-4298.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.8.4289-4298.2004</ArticleId><ArticleId IdType="pmc">PMC374262</ArticleId><ArticleId IdType="pubmed">15047842</ArticleId></ArticleIdList></Reference><Reference><Citation>Racaniello V.R. Chapter24, The Picornaviridae; The Viruses and Their Replication. Fields Virology. 5th ed. Volume 1. Wolters Kluwer Health/Lippincott Williams &amp; Wilkins; Philadelphia, PA, USA: 2007. p. 829.</Citation></Reference><Reference><Citation>Lim B.K., Choe S.C., Shin J.O., Ho S.H., Kim J.M., Yu S.S., Kim S., Jeon E.S. Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis. Circulation. 2002;105:1278&#x2013;1281. doi: 10.1161/circ.105.11.1278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circ.105.11.1278</ArticleId><ArticleId IdType="pubmed">11901035</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim B.K., Choi J.H., Nam J.H., Gil C.O., Shin J.O., Yun S.H., Kim D.K., Jeon E.S. Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis. Cardiovasc. Res. 2006;71:517&#x2013;526. doi: 10.1016/j.cardiores.2006.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardiores.2006.05.016</ArticleId><ArticleId IdType="pubmed">16806133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim B.K., Yun S.H., Ju E.S., Kim B.K., Lee Y.J., Yoo D.K., Kim Y.C., Jeon E.S. Soluble coxsackievirus B3 3C protease inhibitor prevents cardiomyopathy in an experimental chronic myocarditis murine model. Virus Res. 2015;199:1&#x2013;8. doi: 10.1016/j.virusres.2014.11.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2014.11.030</ArticleId><ArticleId IdType="pubmed">25485472</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.M., Lim B.K., Ho S.H., Yun S.H., Shin J.O., Park E.M., Kim D.K., Kim S., Jeon E.S. TNFR-Fc fusion protein expressed by in vivo electroporation improves survival rates and myocardial injury in coxsackievirus induced murine myocarditis. Biochem. Biophys. Res. Commun. 2006;344:765&#x2013;771. doi: 10.1016/j.bbrc.2006.03.170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.03.170</ArticleId><ArticleId IdType="pubmed">16631119</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore M.J. From birth to death: The complex lives of eukaryotic mRNAs. Science. 2005;309:1514&#x2013;1518. doi: 10.1126/science.1111443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1111443</ArticleId><ArticleId IdType="pubmed">16141059</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanner N.K., Linder P. DExD/H box RNA helicases: From generic motors to specific dissociation functions. Mol. Cell. 2001;8:251&#x2013;262. doi: 10.1016/S1097-2765(01)00329-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1097-2765(01)00329-X</ArticleId><ArticleId IdType="pubmed">11545728</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky E., Gross C.H., Shuman S., Pyle A.M. Active disruption of an RNA-protein interaction by a DExH/D RNA helicase. Science. 2001;291:121&#x2013;125. doi: 10.1126/science.291.5501.121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.291.5501.121</ArticleId><ArticleId IdType="pubmed">11141562</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulvila J., Hultmark D., Ramet M. RNA silencing in the antiviral innate immune defence&#x2014;Role of DEAD-box RNA helicases. Scand. J. Immunol. 2010;71:146&#x2013;158. doi: 10.1111/j.1365-3083.2009.02362.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3083.2009.02362.x</ArticleId><ArticleId IdType="pubmed">20415780</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranji A., Boris-Lawrie K. RNA helicases: Emerging roles in viral replication and the host innate response. RNA Biol. 2010;7:775&#x2013;787. doi: 10.4161/rna.7.6.14249.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/rna.7.6.14249</ArticleId><ArticleId IdType="pmc">PMC3073335</ArticleId><ArticleId IdType="pubmed">21173576</ArticleId></ArticleIdList></Reference><Reference><Citation>Yedavalli V.S., Zhang N., Cai H., Zhang P., Starost M.F., Hosmane R.S., Jeang K.T. Ring expanded nucleoside analogues inhibit RNA helicase and intracellular human immunodeficiency virus type 1 replication. J. Med. Chem. 2008;51:5043&#x2013;5051. doi: 10.1021/jm800332m.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm800332m</ArticleId><ArticleId IdType="pmc">PMC2537995</ArticleId><ArticleId IdType="pubmed">18680273</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkert S., Westermann D., Wang X., Klingel K., Dorner A., Savvatis K., Grossl T., Krohn S., Tschope C., Zeichhardt H., et al. Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor. Circulation. 2009;120:2358&#x2013;2366. doi: 10.1161/CIRCULATIONAHA.108.845339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.845339</ArticleId><ArticleId IdType="pubmed">19933937</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>